

LIST OF FIGURES

Figure	Title	Page
2.1.	Schematic diagram of particle absorption by M-cells	24
2.2.	Illustrative mechanism of third-generation calcium channel blockers	31
3.1.	UV spectra of lercanidipine hydrochloride	57
3.2.	FTIR spectra of lercanidipine hydrochloride	58
3.3.	Typical chromatogram of lercanidipine hydrochloride	60
3.4.	Representative chromatogram of rabbit blank plasma (b) and plasma spiked with standard lercanidipine and IS (a)	64
4.1.	FTIR spectra of pure drug lercanidipine (a), physical mixture of Lercanidipine + SPC + Cholesterol + Trehalose (LSCT) (b), Lercanidipine + HSPC + Cholesterol + Trehalose (LHCT) (c), Lercanidipine + EPC +Cholesterol + Trehalose (LECT) (d)	92
4.2.	DSC thermograms of pure drug lercanidipine (a), physical mixture of Lercanidipine + SPC +Cholesterol +Trehalose (LSCT) (b), Lercanidipine + HSPC +Cholesterol +Trehalose (LHCT) (c), Lercanidipine + EPC +Cholesterol +Trehalose (LECT) (d)	93
4.3.	Solubility profile of lercanidipine in water and different pH conditions	94
4.4a.	Comparative graph showing effect of different concentrations of SPC and cholesterol on particle size and PDI of lercanidipine nanoproliposomes	98
4.4b.	Encapsulation efficiency of lercanidipine nanoproliposomes with different concentration of SPC and cholesterol	98
4.4c.	Comparative graph showing effect of different concentrations of HSPC and cholesterol on particle size and PDI of lercanidipine nanoproliposomes	99
4.4d.	Encapsulation efficiency of lercanidipine nanoproliposomes with different concentration of HSPC and cholesterol	99
4.4e.	Comparative graph showing effect of different concentrations of EPC and cholesterol on particle size and PDI of LER nanoproliposome	100
4.4f.	Encapsulation efficiency of lercanidipine nanoproliposomes with different concentration of EPC and cholesterol	100
4.5.	Effect of homogenization pressure on the particle size of lercanidipine nanoproliposomes	102
4.6.	Evaluation of various cryoprotectants and their influence on the particle size of LER nanoproliposomes after reconstitution	103

4.7.	Effect of trehalose concentration on the particle size and %EE of freeze dried lercanidipine loaded nanoproliposomes	105
4.8a.	Typical particle size distribution of the lercanidipine nanoproliposomes (B. No. PL-06)	107
4.8b.	Zeta potential profile of the lercanidipine nanoproliposomes (B. No. PL-06)	107
4.8c.	Typical particle size distribution of the lercanidipine nanoproliposomes (B. No. PL-10)	107
4.8d.	Zeta potential profile of the lercanidipine nanoproliposomes (B. No. PL-10)	108
4.8e.	Typical particle size distribution of the lercanidipine nanoproliposomes (B. No. PL-19)	108
4.8f.	Zeta potential profile of the LER nanoproliposomes (B. No. PL-19)	108
4.9.	<i>In vitro</i> percentage drug release of pure drug and selected batches of freeze dried lercanidipine nanoproliposomes. (a) Pure drug, (b) SPC nanoproliposomes, (c) HSPC nanoproliposomes and (d) EPC nanoproliposomes.	111
4.10.	Atomic force micrograph topography images of freeze dried LER nanoproliposomes (a) PL-06 (10 × 10 μm), (b) PL-10 (1 × 1 μm) and (c) PL-19 (10 × 10 μm)	113
4.11.	Transmission electron microscopy image of LER loaded nanoproliposomes (magnification range of 25 k - 100 k ×) (a) SPC formulation (PL-06), (b) HSPC formulation (PL-10) and (c) EPC formulation (PL-19)	114
4.12.	FTIR spectra of (a) PL-06, (b) PL-10 and (c) PL-19	115
4.13.	Differential scanning calorimetry thermograms of (a) PL-06, (b) PL-10 and (c) PL-19	117
4.14.	X-ray diffraction patterns of (a) LER, (b) B. No. PL-06, (c) B. No. PL-10 and (d) B. No. PL-19	119
4.15.	Comparative chart of <i>in situ</i> absorption of LER nanoproliposomes in rat intestine compared with free LER	121
4.16a.	Mean plasma concentration versus time profile for lercanidipine following intravenous administration.	123
4.16b.	Comparative mean plasma concentration versus time profile for lercanidipine and lercanidipine loaded nanoproliposomes (B. No. PL-06) following oral administration	124

4.17.	Antihypertensive activity of different treatment groups (sham-control and uninephrectomized DOCA control, pure drug and lercanidipine loaded nanoproliposomes; B. No. PL-06)	126
5.1.	FTIR spectra of pure drug Lercanidipine (a), physical mixture of Lercanidipine + PLGA 50:50 + PVA + Mannitol (LPPM) (b), Lercanidipine + Eudragit RLPO + PVA + Mannitol (LEPM) (c), Lercanidipine + Gantrez AN-119BF + PVA + Mannitol (LGPM) (d)	154
5.2.	DSC thermograms of pure drug Lercanidipine (a), physical mixture of Lercanidipine + PLGA 50:50 + PVA + Mannitol (LPPM) (b), Lercanidipine + Eudragit RLPO + PVA + Mannitol (LEPM) (c), Lercanidipine + Gantrez AN-119BF + PVA + Mannitol (LGPM) (d)	155
5.3a.	Particle size and polydispersity index of LER loaded nanoparticles as a function of increasing PLGA weight ratio with respect to lercanidipine	159
5.3b.	Effect of Drug: Polymer ratio on the drug encapsulation efficiency of PLGA based lercanidipine nanoparticles	159
5.3c.	Particle size and polydispersity index of lercanidipine loaded nanoparticles as a function of increasing Eudragit RLPO weight ratio with respect to LER	160
5.3d.	Effect of Drug: Polymer ratio on the drug encapsulation efficiency of Eudragit RLPO based lercanidipine nanoparticles	160
5.3e.	Particle size and polydispersity index of lercanidipine loaded nanoparticles as a function of increasing Gantrez AN-119BF weight ratio with respect to LER	161
5.3f.	Effect of Drug: Polymer ratio on the drug encapsulation efficiency of Gantrez AN-119BF based lercanidipine nanoparticles	161
5.4.	Comparative graph illustrating effect of various surfactants on particle size and % encapsulation efficiency of lercanidipine nanoparticles	163
5.5.	Effect of PVA concentration on the particle size and polydispersity index of lercanidipine nanoparticles	164
5.6.	Influence of homogenization speed used during emulsification step on the particle size of lercanidipine loaded nanoparticles	166
5.7	Effect of probe sonication amplitude on particle size of lercanidipine loaded nanoparticles	167
5.8.	The influence of various cryoprotectants on the particle size and %EE of freeze-dried lercanidipine loaded nanoparticles.	170
5.9.	Effect of mannitol concentration on the particle size and %EE of freeze	170

	dried lercanidipine loaded nanoparticles	
5.10a.	Typical particle size distribution of the lercanidipine nanoparticles (B. No. PN-05)	171
5.10b.	Zeta potential profile of the lercanidipine nanoparticles (B. No. PN-05)	171
5.10c.	Typical particle size distribution of the lercanidipine nanoparticles (B. No. PN-13)	171
5.10d.	Zeta potential profile of the lercanidipine nanoparticles (B. No. PN-13).	172
5.10e.	Typical particle size distribution of the lercanidipine nanoparticles (B. No. PN-19)	172
5.10f.	Zeta potential profile of the lercanidipine nanoparticles (B. No. PN-19)	172
5.11.	<i>In vitro</i> percentage drug release of pure drug and selected batches of freeze dried lercanidipine nanoparticles (a) Pure drug, (b) PLGA 50:50 nanoparticles, (c) Eudragit RLPO nanoparticles and (d) Gantrez AN-119BF nanoparticles	175
5.12.	Atomic force micrograph topography images of freeze dried lercanidipine nanoparticles (a) PN-05 (10 × 10 μm), (b) PN-13 (2.5 × 2.5 μm) and (c) PN-19 (10 × 10 μm)	177
5.13.	Transmission electron microscopy image of freeze dried lercanidipine loaded nanoparticles (magnification range of 4 k -15.0 k ×) (a) PN-05, (b) PN-13 and (c) PN-19	178
5.14.	FTIR spectra of (a) PN-05, (b) PN-13 and (c) PN-19	179
5.15.	Differential scanning calorimetry thermograms of (a) PN-05, (b) PN-13 and (c) PN-19	181
5.16.	X-ray diffraction patterns of (a) LER, (b) B. No. PN-05, (c) B. No. PN-13 and (d) B. No. PN-19	183
5.17.	Comparative chart of <i>in situ</i> absorption of LER nanoparticles in rat intestine compared with free lercanidipine.	185
5.18.	Comparative mean plasma concentration versus time profile for LER and lercanidipine loaded nanoparticles (B. No. PN-05) following oral administration	186
5.19.	Antihypertensive activity of different treatment groups (sham and uninephrectomized DOCA-control, pure drug and lercanidipine loaded nanoparticles; B. No. PN-05)	190